ISSN 2147-9720 | E-ISSN 2148-4279
Original Article
IL1-blocking therapy in colchicine-resistant familial Mediterranean fever
1 Division of Rheumatology, Department of Internal Medicine, Heidelberg University Hospital, Heidelberg, Germany  
Eur J Rheumatol 2018; 5: 230-234
DOI: 10.5152/eurjrheum.2018.18036
Key Words: Familial Mediterranean fever, colchicin, amyloidosis, IL1
Abstract

 

Objective: Approximately 10%-20% of patients with familial Mediterranean fever (FMF) show an inadequate response to colchicine. In our cohort study, patients with FMF with or without amyloidosis and with an inadequate response to colchicine were treated with anakinra or canakinumab.


Methods
: Clinical and laboratory parameters, Mediterranean fever (MEFV) mutations, and patient-reported outcomes were analyzed in 31 patients treated with anakinra or canakinumab.


Results
: In a cohort of 250 adult patients with FMF, 31 patients were treated with anakinra (n=29) or canakinumab (n=2). The median Pras FMF severity score was 8 (range, 5-14) and correlated with the presence of high-penetrance MEFV mutations (p.Met-694-Val or p.Met-680-Ile). The FMF severity score was 11 in patients with two high-penetrance MEFV mutations (68%), 9 in those with a single high-penetrance MEFV mutation (19%), and 7.5 in those without high-penetrance MEFV mutations (13%, p=0.2). FMF-related amyloid A amyloidosis was diagnosed in 12 (39%) patients. Anakinra was used daily in 20 patients, thrice a week in 7, and upon demand during attacks in 2. Two patients were treated with canakinumab. IL-1-blocking treatment showed a rapid (2±3 days) and persistent suppression of FMF symptoms and inflammatory parameters. The frequency of FMF attacks was significantly reduced (p<0.003). Both patient- and physician-reported FMF activity significantly improved (p<0.0001).


Conclusion
: IL-1-blocking therapy was well tolerated over a median period of 2 years and reduced the frequency of FMF attacks in patients with colchicine-resistant FMF.


Cite this article as
: Köhler BM, Lorenz HM, Blank N. IL1-blocking therapy in colchicine-resistant familial Mediterranean fever. Eur J Rheumatol 2018; 5: 230-4.

Key Words
Authors
All
Author’s Corner
Survey
AVES | Copyright © 2018 Medical Research and Education Association | Latest Update: 27.11.2018